A monoclonal antibody is an antibody derived from a single antibody-producing cell clone or produced recombinantly from a defined antibody sequence. Conventional monoclonal antibodies share the same antigen-binding regions and recognize a particular site on an antigen. Their reproducible specificity distinguishes them from polyclonal antibody preparations, which contain antibodies from multiple clones. Monoclonal antibodies are used as laboratory reagents, diagnostic tools, and therapeutic agents in medicine. (nobelprize.org)
Biological basis and structure
Natural antibodies are proteins produced by B cells and their differentiated descendants. They participate in the immune system by recognizing molecular structures and supporting their neutralization or removal. A monoclonal antibody reproduces one selected antibody specificity rather than the diverse mixture generated during a typical immune response. (ncbi.nlm.nih.gov)
Most therapeutic monoclonal antibodies belong to the immunoglobulin G (IgG) class. A conventional IgG molecule has a Y-shaped structure comprising two identical heavy chains and two identical light chains. Variable regions at the tips form antigen-binding sites; their amino acid sequences determine recognition of an epitope, the particular molecular feature contacted by the antibody. The stem, called the Fc region, interacts with immune cells and helps mediate biological responses. (fda.gov)
Specificity is not equivalent to absolute exclusivity. An antibody can bind structurally similar epitopes on different molecules, a phenomenon known as cross-reactivity. Conversely, changes in an epitope’s shape or accessibility can alter binding. The term “monoclonal” describes a defined antibody lineage or sequence; it does not guarantee that every molecule in a manufactured preparation has identical chemical modifications. (ncbi.nlm.nih.gov)
Discovery and production
In 1975, Georges Köhler and César Milstein described hybridoma technology, a method for generating continuously growing cells that secrete antibodies of predetermined specificity. They fused antibody-producing cells with myeloma cells, combining antibody production with sustained growth in culture. Selected hybrid cells could then be cloned and expanded. Köhler and Milstein shared the 1984 Nobel Prize in Physiology or Medicine with Niels Jerne, whose work concerned immune-system specificity and regulation. (nobelprize.org)
Hybridoma production involves screening cells for the required binding properties and isolating a suitable clone. Antibodies can also be produced through recombinant DNA methods: sequences encoding the antibody chains are introduced into host cells that express the protein. Phage display provides another route to discovery, linking displayed antibody fragments to their encoding sequences so that binders can be selected. These approaches separate antibody discovery from subsequent large-scale production. (fda.gov)
Early mouse-derived antibodies could provoke immune responses when administered to humans. Antibody engineering introduced chimeric antibodies, which combine nonhuman variable regions with human constant regions, and humanized antibodies, which retain selected nonhuman binding sequences within predominantly human frameworks. Fully human antibodies can also be generated using recombinant selection methods. These categories describe sequence design, not a guarantee that a product cannot trigger an immune response. (nobelprize.org)
Therapeutic mechanisms
Monoclonal antibodies act through several distinct mechanisms. Some block the interaction between a receptor and its signaling partner; others bind soluble mediators. For example, adalimumab binds tumor necrosis factor alpha, a cytokine involved in inflammation, and inhibits its interaction with cell-surface receptors. Antibody medicines therefore include agents used for immune-mediated disorders as well as cancer. (fda.gov)
Other antibodies help immune cells recognize and destroy target cells. Rituximab binds CD20 on B cells, including certain malignant B cells, and promotes their elimination. This illustrates how an antibody’s target determines which cell populations it affects; binding need not be restricted to cancer cells. (cancer.gov)
Engineered formats extend these mechanisms. A bispecific antibody has two different binding specificities. Blinatumomab binds CD19 on target cells and CD3 on T cells, bringing the cells together to facilitate immune-mediated killing. An antibody–drug conjugate chemically links an antibody to a drug, combining target recognition with delivery of a cell-killing substance. Such constructs differ from unmodified antibodies in both activity and potential toxicity. (cancer.gov)
Research and diagnostic applications
Outside treatment, monoclonal antibodies identify molecular targets in cells, tissues, and biological samples. Their defined specificity supports diagnostic characterization, identification of cell populations, and investigation of antigen structure. They can also serve as capture reagents in affinity chromatography, allowing a target substance to be separated from a mixture. (nobelprize.org)
Reagent performance requires characterization rather than reliance on the monoclonal designation alone. The National Cancer Institute’s antibody characterization program evaluates renewable affinity reagents for research applications, including tissue staining and protein-measurement assays. Such testing establishes whether a reagent performs appropriately under the conditions of a particular method. (dctd.cancer.gov)
Safety and product quality
Adverse effects depend on the antibody, its target, formulation, and dose. Therapeutic antibodies can cause infusion reactions, injection-site reactions, or allergic reactions. Some produce target-related organ effects; certain immune-activating antibodies can cause cytokine release syndrome. These risks are not uniform across the class. (cancer.gov)
Manufacturing quality also matters. Antibodies can vary in attached sugar structures and other chemical characteristics, requiring analytical control of product heterogeneity. A biosimilar antibody is evaluated against an approved reference biologic; in the United States, it must be highly similar and have no clinically meaningful differences in safety, purity, or potency. Biosimilarity is therefore an evidence-based regulatory determination, not simply shared binding to the same antigen. (accessdata.fda.gov)